Skip to content

Study · Systematic review · 2026

12 results

Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.

Zufry H, Hariyanto TI

Obesity research & clinical practice20 Feb 2026Cited by 1 (Europe PMC)

PMID41723034 (opens in a new tab)DOI10.1016/j.orcp.2026.02.002 (opens in a new tab)PepBankPUB-41723034
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of studies in people with overweight or obesity, tirzepatide gave a significantly greater percentage body weight reduction than semaglutide (MD -4.61 %).

    In plain wordsIn people with overweight or obesity, tirzepatide led to a greater percent weight loss than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercentage body weight change versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    MD, percentage weight change
    −4.61%
    tirzepatide versus semaglutide

    Source sentences

    Summary
    Tirzepatide was associated with significantly greater percentage body weight reduction (MD -4.61 %; 95 % CI: -6.03, -3.20; p < 0.00001; I²=95 %) and absolute weight loss (MD -4.76 kg; 95 % CI: -6.09, -3.42; p < 0.00001; I²=87 %) compared with semaglutide.
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of studies in people with overweight or obesity, semaglutide gave a significantly smaller percentage body weight reduction than tirzepatide (MD -4.61 % for tirzepatide versus semaglutide).

    In plain wordsIn people with overweight or obesity, semaglutide led to a smaller percent weight loss than tirzepatide.

    Peptide
    Semaglutide
    Outcome
    IncreasePercentage body weight change versus tirzepatide
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    MD, percentage weight change
    −4.61%
    tirzepatide versus semaglutide

    Source sentences

    Summary
    Tirzepatide was associated with significantly greater percentage body weight reduction (MD -4.61 %; 95 % CI: -6.03, -3.20; p < 0.00001; I²=95 %) and absolute weight loss (MD -4.76 kg; 95 % CI: -6.09, -3.42; p < 0.00001; I²=87 %) compared with semaglutide.
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  3. 03HumanSystematic reviewEfficacy outcome

    In a meta-analysis of studies in people with overweight or obesity, tirzepatide gave greater absolute weight loss than semaglutide (MD -4.76 kg).

    In plain wordsIn people with overweight or obesity, tirzepatide led to more kilograms lost than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAbsolute body weight change versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    MD, absolute weight loss
    −4.76 kg
    tirzepatide versus semaglutide

    Source sentences

    Summary
    Tirzepatide was associated with significantly greater percentage body weight reduction (MD -4.61 %; 95 % CI: -6.03, -3.20; p < 0.00001; I²=95 %) and absolute weight loss (MD -4.76 kg; 95 % CI: -6.09, -3.42; p < 0.00001; I²=87 %) compared with semaglutide.
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  4. 04HumanSystematic reviewEfficacy outcome

    In a meta-analysis of studies in people with overweight or obesity, semaglutide gave smaller absolute weight loss than tirzepatide (MD -4.76 kg for tirzepatide versus semaglutide).

    In plain wordsIn people with overweight or obesity, semaglutide led to fewer kilograms lost than tirzepatide.

    Peptide
    Semaglutide
    Outcome
    IncreaseAbsolute body weight change versus tirzepatide
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    MD, absolute weight loss
    −4.76 kg
    tirzepatide versus semaglutide

    Source sentences

    Summary
    Tirzepatide was associated with significantly greater percentage body weight reduction (MD -4.61 %; 95 % CI: -6.03, -3.20; p < 0.00001; I²=95 %) and absolute weight loss (MD -4.76 kg; 95 % CI: -6.09, -3.42; p < 0.00001; I²=87 %) compared with semaglutide.
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  5. 05HumanSystematic reviewEfficacy outcome

    A higher proportion of participants on tirzepatide than on semaglutide achieved weight loss of 5 % or more (OR 1.52).

    In plain wordsMore people on tirzepatide than on semaglutide lost at least 5 % of their weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight loss of 5 % or more
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    OR
    1.52 ratio
    weight loss >= 5 %, tirzepatide versus semaglutide

    Source sentences

    Summary
    Higher proportions of participants treated with tirzepatide achieved ≥ 5 % (OR 1.52; 95 % CI: 1.03-2.25; p = 0.04; I²=97 %), ≥ 10 % (OR 2.33; 95 % CI: 1.77-3.07; p < 0.00001; I²=95 %), ≥ 15 % (OR 2.82; 95 % CI: 2.06-3.87; p < 0.00001; I²=96 %), and ≥ 20 % (OR 2.28; 95 % CI: 1.62-3.21; p < 0.00001; I…
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  6. 06HumanSystematic reviewEfficacy outcome

    A lower proportion of participants on semaglutide than on tirzepatide achieved weight loss of 5 % or more (OR 1.52 for tirzepatide versus semaglutide).

    In plain wordsFewer people on semaglutide than on tirzepatide lost at least 5 % of their weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss of 5 % or more
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    OR
    1.52 ratio
    weight loss >= 5 %, tirzepatide versus semaglutide

    Source sentences

    Summary
    Higher proportions of participants treated with tirzepatide achieved ≥ 5 % (OR 1.52; 95 % CI: 1.03-2.25; p = 0.04; I²=97 %), ≥ 10 % (OR 2.33; 95 % CI: 1.77-3.07; p < 0.00001; I²=95 %), ≥ 15 % (OR 2.82; 95 % CI: 2.06-3.87; p < 0.00001; I²=96 %), and ≥ 20 % (OR 2.28; 95 % CI: 1.62-3.21; p < 0.00001; I…
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  7. 07HumanSystematic reviewEfficacy outcome

    A higher proportion of participants on tirzepatide than on semaglutide achieved weight loss of 10 % or more (OR 2.33).

    In plain wordsMore people on tirzepatide than on semaglutide lost at least 10 % of their weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight loss of 10 % or more
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    OR
    2.33 ratio
    weight loss >= 10 %, tirzepatide versus semaglutide

    Source sentences

    Summary
    Higher proportions of participants treated with tirzepatide achieved ≥ 5 % (OR 1.52; 95 % CI: 1.03-2.25; p = 0.04; I²=97 %), ≥ 10 % (OR 2.33; 95 % CI: 1.77-3.07; p < 0.00001; I²=95 %), ≥ 15 % (OR 2.82; 95 % CI: 2.06-3.87; p < 0.00001; I²=96 %), and ≥ 20 % (OR 2.28; 95 % CI: 1.62-3.21; p < 0.00001; I…
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  8. 08HumanSystematic reviewEfficacy outcome

    A lower proportion of participants on semaglutide than on tirzepatide achieved weight loss of 10 % or more (OR 2.33 for tirzepatide versus semaglutide).

    In plain wordsFewer people on semaglutide than on tirzepatide lost at least 10 % of their weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss of 10 % or more
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    OR
    2.33 ratio
    weight loss >= 10 %, tirzepatide versus semaglutide

    Source sentences

    Summary
    Higher proportions of participants treated with tirzepatide achieved ≥ 5 % (OR 1.52; 95 % CI: 1.03-2.25; p = 0.04; I²=97 %), ≥ 10 % (OR 2.33; 95 % CI: 1.77-3.07; p < 0.00001; I²=95 %), ≥ 15 % (OR 2.82; 95 % CI: 2.06-3.87; p < 0.00001; I²=96 %), and ≥ 20 % (OR 2.28; 95 % CI: 1.62-3.21; p < 0.00001; I…
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  9. 09HumanSystematic reviewEfficacy outcome

    A higher proportion of participants on tirzepatide than on semaglutide achieved weight loss of 15 % or more (OR 2.82).

    In plain wordsMore people on tirzepatide than on semaglutide lost at least 15 % of their weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight loss of 15 % or more
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    OR
    2.82 ratio
    weight loss >= 15 %, tirzepatide versus semaglutide

    Source sentences

    Summary
    Higher proportions of participants treated with tirzepatide achieved ≥ 5 % (OR 1.52; 95 % CI: 1.03-2.25; p = 0.04; I²=97 %), ≥ 10 % (OR 2.33; 95 % CI: 1.77-3.07; p < 0.00001; I²=95 %), ≥ 15 % (OR 2.82; 95 % CI: 2.06-3.87; p < 0.00001; I²=96 %), and ≥ 20 % (OR 2.28; 95 % CI: 1.62-3.21; p < 0.00001; I…
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  10. 10HumanSystematic reviewEfficacy outcome

    A lower proportion of participants on semaglutide than on tirzepatide achieved weight loss of 15 % or more (OR 2.82 for tirzepatide versus semaglutide).

    In plain wordsFewer people on semaglutide than on tirzepatide lost at least 15 % of their weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss of 15 % or more
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    OR
    2.82 ratio
    weight loss >= 15 %, tirzepatide versus semaglutide

    Source sentences

    Summary
    Higher proportions of participants treated with tirzepatide achieved ≥ 5 % (OR 1.52; 95 % CI: 1.03-2.25; p = 0.04; I²=97 %), ≥ 10 % (OR 2.33; 95 % CI: 1.77-3.07; p < 0.00001; I²=95 %), ≥ 15 % (OR 2.82; 95 % CI: 2.06-3.87; p < 0.00001; I²=96 %), and ≥ 20 % (OR 2.28; 95 % CI: 1.62-3.21; p < 0.00001; I…
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  11. 11HumanSystematic reviewEfficacy outcome

    A higher proportion of participants on tirzepatide than on semaglutide achieved weight loss of 20 % or more (OR 2.28).

    In plain wordsMore people on tirzepatide than on semaglutide lost at least 20 % of their weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight loss of 20 % or more
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    OR
    2.28 ratio
    weight loss >= 20 %, tirzepatide versus semaglutide

    Source sentences

    Summary
    Higher proportions of participants treated with tirzepatide achieved ≥ 5 % (OR 1.52; 95 % CI: 1.03-2.25; p = 0.04; I²=97 %), ≥ 10 % (OR 2.33; 95 % CI: 1.77-3.07; p < 0.00001; I²=95 %), ≥ 15 % (OR 2.82; 95 % CI: 2.06-3.87; p < 0.00001; I²=96 %), and ≥ 20 % (OR 2.28; 95 % CI: 1.62-3.21; p < 0.00001; I…
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.
  12. 12HumanSystematic reviewEfficacy outcome

    A lower proportion of participants on semaglutide than on tirzepatide achieved weight loss of 20 % or more (OR 2.28 for tirzepatide versus semaglutide).

    In plain wordsFewer people on semaglutide than on tirzepatide lost at least 20 % of their weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss of 20 % or more
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    OR
    2.28 ratio
    weight loss >= 20 %, tirzepatide versus semaglutide

    Source sentences

    Summary
    Higher proportions of participants treated with tirzepatide achieved ≥ 5 % (OR 1.52; 95 % CI: 1.03-2.25; p = 0.04; I²=97 %), ≥ 10 % (OR 2.33; 95 % CI: 1.77-3.07; p < 0.00001; I²=95 %), ≥ 15 % (OR 2.82; 95 % CI: 2.06-3.87; p < 0.00001; I²=96 %), and ≥ 20 % (OR 2.28; 95 % CI: 1.62-3.21; p < 0.00001; I…
    1 context sentence
    Summary · context
    A systematic search of Europe PMC, Medline, Scopus, and the Cochrane Library was conducted to identify eligible randomized controlled trials (RCTs) and observational studies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.